首页 > 最新文献

ecancermedicalscience最新文献

英文 中文
Feasibility and impact of knowledge-based automated radiotherapy treatment planning in low- and middle-income countries. 基于知识的自动化放射治疗计划在中低收入国家的可行性和影响。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1988
Awusi Kavuma, Solomon Kibudde, Yao Hao, Baozhou Sun

Background and purpose: A high-quality treatment planning process is crucial in advanced radiotherapy techniques to ensure adequate dose to the target volume (TV) and sparing of organs at risk (OARs). This process often requires intensive labor, creating barriers for deployment in low- and middle-income countries (LMICs). We aimed to establish the feasibility of implementing knowledge-based auto-planning to facilitate clinical efficiency and increase patient throughput in an LMIC.

Materials and methods: We evaluated 60 randomly selected VMAT manual plans (VMPs), including 10 for each of the following sites: head and neck, oesophagus, breast, prostate, cervical, and rectal cancers. Using the same CT-structure datasets, volumetric modulated arc therapy auto-plans (VAPs), which involved matching the patient's CT-structure datasets with corresponding model structures before optimisation, were generated using RapidPlan® knowledge-based models. The plans were compared using different dosimetric parameters, average planning times (APT) and plan scores, the latter of which was used for quantification of plan quality.

Results: The APT was 29.5 ± 3.0 minutes for VAPs compared to 43.2 ± 12.0 minutes for VMPs (p < 0.01), an approximate 33.0% time saving. The average plan scores were 73.9% ± 9.5% and 74.8% ± 10.5% for VAPs and VMPs, respectively (p = 0.50). The average homogeneity and conformity indices were 0.12 ± 0.05 and 0.93 ± 0.04 for VAPs compared to 0.09 ± 0.04 and 0.94 ± 0.03 for VMPs, respectively. For prostate and breast cases, both methods achieved the rectum's V50Gy ≤ 50% and spinal cord's Dmax ≤ 39.0 Gy constraints; however, VAPs projected lower doses than the corresponding VMPs (16.5 ± 4.3 versus 30.6 ± 13.1: p = 0.01) and (6.0 ± 1.6 versus 19.6 ± 2.3: p < 0.01).

Conclusion: The knowledge-based VAP-generated technique offers adequate dose coverage, homogeneity and conformity to the TV while sparing OARs, is less dependent on the planner's experience, saves planning time and holds tremendous potential for improving radiotherapy workflow in LMICs.

背景和目的:高质量的治疗计划过程在高级放疗技术中至关重要,以确保足够的剂量达到靶体积(TV)和保留危险器官(OARs)。这一过程往往需要密集的劳动,为在低收入和中等收入国家(LMICs)部署制造了障碍。我们的目标是建立实施基于知识的自动计划的可行性,以促进临床效率和提高LMIC的患者吞吐量。材料和方法:我们评估了60个随机选择的VMAT手册计划(VMPs),包括以下部位各10个:头颈部、食道癌、乳腺癌、前列腺癌、宫颈癌和直肠癌。使用相同的ct结构数据集,使用基于RapidPlan®知识的模型生成容积调制弧线治疗自动计划(VAPs),该计划涉及在优化之前将患者的ct结构数据集与相应的模型结构进行匹配。采用不同剂量学参数、平均计划时间(APT)和计划评分进行比较,后者用于量化计划质量。结果:VAPs的APT为29.5±3.0 min, VMPs为43.2±12.0 min (p < 0.01),约节省33.0%的时间。vap和VMPs的平均计划得分分别为73.9%±9.5%和74.8%±10.5% (p = 0.50)。VAPs的平均均匀性和一致性指数分别为0.12±0.05和0.93±0.04,而VMPs的平均均匀性和一致性指数分别为0.09±0.04和0.94±0.03。对于前列腺和乳腺病例,两种方法均达到直肠V50Gy≤50%和脊髓Dmax≤39.0 Gy的约束;然而,VAPs预测的剂量低于相应的VMPs(16.5±4.3比30.6±13.1:p = 0.01)和(6.0±1.6比19.6±2.3:p < 0.01)。结论:基于知识的vap生成技术具有足够的剂量覆盖、均匀性和与TV的一致性,同时节省了OARs,对计划者经验的依赖较少,节省了计划时间,在改善低收入国家放疗工作流程方面具有巨大的潜力。
{"title":"Feasibility and impact of knowledge-based automated radiotherapy treatment planning in low- and middle-income countries.","authors":"Awusi Kavuma, Solomon Kibudde, Yao Hao, Baozhou Sun","doi":"10.3332/ecancer.2025.1988","DOIUrl":"10.3332/ecancer.2025.1988","url":null,"abstract":"<p><strong>Background and purpose: </strong>A high-quality treatment planning process is crucial in advanced radiotherapy techniques to ensure adequate dose to the target volume (TV) and sparing of organs at risk (OARs). This process often requires intensive labor, creating barriers for deployment in low- and middle-income countries (LMICs). We aimed to establish the feasibility of implementing knowledge-based auto-planning to facilitate clinical efficiency and increase patient throughput in an LMIC.</p><p><strong>Materials and methods: </strong>We evaluated 60 randomly selected VMAT manual plans (VMPs), including 10 for each of the following sites: head and neck, oesophagus, breast, prostate, cervical, and rectal cancers. Using the same CT-structure datasets, volumetric modulated arc therapy auto-plans (VAPs), which involved matching the patient's CT-structure datasets with corresponding model structures before optimisation, were generated using RapidPlan<sup>®</sup> knowledge-based models. The plans were compared using different dosimetric parameters, average planning times (APT) and plan scores, the latter of which was used for quantification of plan quality.</p><p><strong>Results: </strong>The APT was 29.5 ± 3.0 minutes for VAPs compared to 43.2 ± 12.0 minutes for VMPs (<i>p</i> < 0.01), an approximate 33.0% time saving. The average plan scores were 73.9% ± 9.5% and 74.8% ± 10.5% for VAPs and VMPs, respectively (<i>p</i> = 0.50). The average homogeneity and conformity indices were 0.12 ± 0.05 and 0.93 ± 0.04 for VAPs compared to 0.09 ± 0.04 and 0.94 ± 0.03 for VMPs, respectively. For prostate and breast cases, both methods achieved the rectum's V50Gy ≤ 50% and spinal cord's Dmax ≤ 39.0 Gy constraints; however, VAPs projected lower doses than the corresponding VMPs (16.5 ± 4.3 versus 30.6 ± 13.1: <i>p</i> = 0.01) and (6.0 ± 1.6 versus 19.6 ± 2.3: <i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>The knowledge-based VAP-generated technique offers adequate dose coverage, homogeneity and conformity to the TV while sparing OARs, is less dependent on the planner's experience, saves planning time and holds tremendous potential for improving radiotherapy workflow in LMICs.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1988"},"PeriodicalIF":1.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A survival analysis of paediatric acute lymphoblastic leukaemia patients at the Moroccan University Hospital Centre of Rabat. 拉巴特摩洛哥大学医院中心儿科急性淋巴细胞白血病患者的生存分析。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1986
Bennani Mechita Nada, Messaoud Sara, Elboukhari Elmamoun Yousra, Amina Kili, El Khorassani Mohammed, Lakhrissi Mariam, Isfaoun Zineb, El Ansari Naoual, Razine Rachid, Obtel Majdouline, El Kababri Maria, Hessissen Laila

Introduction: Acute lymphoblastic leukaemia (ALL) is the most common childhood leukaemia and a significant cause of paediatric mortality worldwide. Morocco, as part of the World Health Organisation (WHO) Global Initiative for Childhood Cancer, aims to achieve a 60% survival rate for paediatric cancers by 2030.

Objective: This study evaluates survival rates and prognostic factors for paediatric ALL patients treated according to the MARALL 2006 protocol at the University Hospital Centre Ibn Sina in Rabat, Morocco.

Methods: A retrospective cohort study analysed data from 512 children diagnosed with ALL between June 2006 and December 2017. Sociodemographic, clinical and therapeutic data were collected. Kaplan-Meier and Cox regression analyses identified survival rates and prognostic factors.

Results: Among the patients, 56.2% achieved complete remission after first-line treatment and 20.9% experienced relapse. The 1-, 3- and 5-year overall survival rates were 83%, 67% and 63%, respectively. Significant prognostic factors included age ≥10 years, white blood cell count >50,000/mm3 and elevated lactate dehydrogenase levels. Standard risk classification and B-cell immunophenotype were associated with better survival outcomes.

Conclusion: This study highlights encouraging survival rates for paediatric ALL patients in Morocco, exceeding the WHO target of 60%. However, achieving the national goal of 80% survival requires further improvements in early diagnosis, treatment access and adoption of advanced therapies.

简介:急性淋巴细胞白血病(ALL)是最常见的儿童白血病,也是全世界儿童死亡的一个重要原因。作为世界卫生组织(世卫组织)儿童癌症全球倡议的一部分,摩洛哥的目标是到2030年实现儿童癌症60%的存活率。目的:本研究评估根据摩洛哥拉巴特伊本西纳大学医院中心MARALL 2006方案治疗的儿科ALL患者的生存率和预后因素。方法:回顾性队列研究分析了2006年6月至2017年12月诊断为ALL的512名儿童的数据。收集社会人口学、临床和治疗数据。Kaplan-Meier和Cox回归分析确定了生存率和预后因素。结果:经一线治疗后,56.2%的患者完全缓解,20.9%的患者复发。1、3、5年总生存率分别为83%、67%、63%。显著预后因素包括年龄≥10岁、白细胞计数50万/mm3和乳酸脱氢酶水平升高。标准风险分类和b细胞免疫表型与更好的生存结果相关。结论:这项研究突出表明,摩洛哥儿科ALL患者的生存率令人鼓舞,超过了世卫组织60%的目标。然而,要实现80%存活率的国家目标,需要进一步改善早期诊断、治疗可及性和采用先进疗法。
{"title":"A survival analysis of paediatric acute lymphoblastic leukaemia patients at the Moroccan University Hospital Centre of Rabat.","authors":"Bennani Mechita Nada, Messaoud Sara, Elboukhari Elmamoun Yousra, Amina Kili, El Khorassani Mohammed, Lakhrissi Mariam, Isfaoun Zineb, El Ansari Naoual, Razine Rachid, Obtel Majdouline, El Kababri Maria, Hessissen Laila","doi":"10.3332/ecancer.2025.1986","DOIUrl":"10.3332/ecancer.2025.1986","url":null,"abstract":"<p><strong>Introduction: </strong>Acute lymphoblastic leukaemia (ALL) is the most common childhood leukaemia and a significant cause of paediatric mortality worldwide. Morocco, as part of the World Health Organisation (WHO) Global Initiative for Childhood Cancer, aims to achieve a 60% survival rate for paediatric cancers by 2030.</p><p><strong>Objective: </strong>This study evaluates survival rates and prognostic factors for paediatric ALL patients treated according to the MARALL 2006 protocol at the University Hospital Centre Ibn Sina in Rabat, Morocco.</p><p><strong>Methods: </strong>A retrospective cohort study analysed data from 512 children diagnosed with ALL between June 2006 and December 2017. Sociodemographic, clinical and therapeutic data were collected. Kaplan-Meier and Cox regression analyses identified survival rates and prognostic factors.</p><p><strong>Results: </strong>Among the patients, 56.2% achieved complete remission after first-line treatment and 20.9% experienced relapse. The 1-, 3- and 5-year overall survival rates were 83%, 67% and 63%, respectively. Significant prognostic factors included age ≥10 years, white blood cell count >50,000/mm<sup>3</sup> and elevated lactate dehydrogenase levels. Standard risk classification and B-cell immunophenotype were associated with better survival outcomes.</p><p><strong>Conclusion: </strong>This study highlights encouraging survival rates for paediatric ALL patients in Morocco, exceeding the WHO target of 60%. However, achieving the national goal of 80% survival requires further improvements in early diagnosis, treatment access and adoption of advanced therapies.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1986"},"PeriodicalIF":1.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leading the fight against liver cancer in Sub-Saharan Africa: developing the first multidisciplinary liver tumour board in Tanzania. 领导撒哈拉以南非洲地区的肝癌防治工作:在坦桑尼亚建立首个多学科肝脏肿瘤委员会。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1987
Ally H Mwanga, Erick M Mbuguje, Jeanine Justiniano, Balowa Musa, Nashivai Kivuyo, Daniel W Kitua, Eva Uiso, Andrew Swallow, Edith Kimambo, Azza Naif, Deogratius B Mwanakulya, Swaleh Pazi, Advera Ngaiza, Seif Wibonela, Behnam Shaygi, Cameron E Gaskill

Background: Multidisciplinary tumour boards (MTBs) are regular meetings of various specialist physicians and healthcare professionals who reach a consensus on diagnostic or therapeutic next steps in a cancer patient's care. They have been used for cancer care worldwide. The benefits of these MTBs are well established in the treatment of cancer, leading to higher rates of care completion and improved overall survival. The authors of this study set out to launch an MTB specifically for liver cancer in Tanzania.

Methodology: In 2023, a multidisciplinary liver tumour board (MLTB) was established at Muhimbili National Hospital in Tanzania. This was designed to promote maximum engagement among medical specialties and international collaborators.

Results: MLTB meetings were held weekly in-person and virtually, where members submit patient cases for review of clinical presentation, imaging, pathology and presumed diagnosis to allow discussion of next steps in diagnosis or treatment. A consensus recommendation is then communicated to the involved departments and the presenting physician proceeds with scheduling the patient for completion of the recommendations.

Conclusion: This MLTB model aims to facilitate a comprehensive multidisciplinary treatment strategy for patients diagnosed with liver cancer. MLTBs are expected to enhance the quality of care provided to patients and promote the utilisation of advanced therapeutic options available in these nations.

背景:多学科肿瘤委员会(MTBs)是各种专科医生和医疗保健专业人员的定期会议,他们就癌症患者的诊断或治疗下一步护理达成共识。它们已被用于世界各地的癌症治疗。这些MTBs的益处在癌症治疗中得到了很好的证实,导致更高的护理完成率和改善的总生存率。这项研究的作者打算在坦桑尼亚推出一种专门针对肝癌的MTB。方法:2023年,在坦桑尼亚Muhimbili国立医院成立了一个多学科肝脏肿瘤委员会。这是为了最大限度地促进医学专业和国际合作者之间的参与。结果:MLTB会议每周举行一次面对面和虚拟会议,成员提交患者病例,审查临床表现,影像学,病理和推定诊断,以便讨论诊断或治疗的下一步。然后将一致的建议传达给相关部门,并由主治医生安排患者完成建议。结论:该MLTB模型旨在促进肝癌患者的综合多学科治疗策略。预计mltb将提高向患者提供的护理质量,并促进这些国家现有先进治疗方案的利用。
{"title":"Leading the fight against liver cancer in Sub-Saharan Africa: developing the first multidisciplinary liver tumour board in Tanzania.","authors":"Ally H Mwanga, Erick M Mbuguje, Jeanine Justiniano, Balowa Musa, Nashivai Kivuyo, Daniel W Kitua, Eva Uiso, Andrew Swallow, Edith Kimambo, Azza Naif, Deogratius B Mwanakulya, Swaleh Pazi, Advera Ngaiza, Seif Wibonela, Behnam Shaygi, Cameron E Gaskill","doi":"10.3332/ecancer.2025.1987","DOIUrl":"10.3332/ecancer.2025.1987","url":null,"abstract":"<p><strong>Background: </strong>Multidisciplinary tumour boards (MTBs) are regular meetings of various specialist physicians and healthcare professionals who reach a consensus on diagnostic or therapeutic next steps in a cancer patient's care. They have been used for cancer care worldwide. The benefits of these MTBs are well established in the treatment of cancer, leading to higher rates of care completion and improved overall survival. The authors of this study set out to launch an MTB specifically for liver cancer in Tanzania.</p><p><strong>Methodology: </strong>In 2023, a multidisciplinary liver tumour board (MLTB) was established at Muhimbili National Hospital in Tanzania. This was designed to promote maximum engagement among medical specialties and international collaborators.</p><p><strong>Results: </strong>MLTB meetings were held weekly in-person and virtually, where members submit patient cases for review of clinical presentation, imaging, pathology and presumed diagnosis to allow discussion of next steps in diagnosis or treatment. A consensus recommendation is then communicated to the involved departments and the presenting physician proceeds with scheduling the patient for completion of the recommendations.</p><p><strong>Conclusion: </strong>This MLTB model aims to facilitate a comprehensive multidisciplinary treatment strategy for patients diagnosed with liver cancer. MLTBs are expected to enhance the quality of care provided to patients and promote the utilisation of advanced therapeutic options available in these nations.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1987"},"PeriodicalIF":1.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of mismatch repair proteins (MLH1 and MSH2) and p53 immunohistochemical expression in prostatic carcinoma: association with different clinicopathologic characteristics. 错配修复蛋白(MLH1和MSH2)和p53免疫组化表达在前列腺癌中的评估:与不同临床病理特征的关系
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-04 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1985
Hend S Abo Safia, Ahmed F Ghaith, Eman E Farghal, Basma S Amer

Background: Prostate cancer (PCa) is one of the most heritable human cancers and it is the second most frequent malignancy in men worldwide. It accounts for a significant morbidity and mortality throughout the world. PCa with mismatch repair (MMR) deficiency often has aggressive clinical and histological features, but its rarity prevents the analysis of the underlying biology. Therefore, in this study, we aimed to evaluate the immunohistochemical expression of MMR proteins and P53 in PCa.

Materials and methods: Fifty cases of PCa were histologically examined. The MMR proteins and P53 immunoexpression were assessed. Also, P53 serum concentration levels using ELIZA was measured and pre-operative prostatic specific antigen (PSA) serum levels were obtained.

Results: There was a significant positive relation between mutS homologue 2 (MSH2) immunoexpression and both PSA serum level and P53 serum concentration (p value 0.001*). Also, there was a significant relation between MSH2 immunoexpression and tumour size, nodal metastasis, distant metastasis and grade grouping. While mutL homologue 1 (MLH1) immunoexpression showed a significant relation with human P53 serum concentrations only (p value 0.035*). Moreover, MLH1 immunoexpression showed only significant relation with nodal metastasis and tumour burden, p value was 0.033* and 0.001*, respectively.

Conclusion: MMR protein loss, especially MSH2, was seen in a significant subset of PCa. Interestingly, it was associated with significantly higher levels of serum PSA and p53. Moreover, it may be associated with unfortunate prognostic features as large tumour size, higher grade grouping and finally nodal and distant metastasis.

背景:前列腺癌(PCa)是最具遗传性的人类癌症之一,是世界范围内男性第二常见的恶性肿瘤。它在全世界造成了很大的发病率和死亡率。错配修复(MMR)缺陷的前列腺癌通常具有侵袭性的临床和组织学特征,但其罕见性阻碍了对潜在生物学的分析。因此,在本研究中,我们旨在评估MMR蛋白和P53在PCa中的免疫组织化学表达。材料与方法:对50例前列腺癌进行组织学检查。检测MMR蛋白和P53的免疫表达。同时,采用elisa法检测血清P53浓度水平,获取术前前列腺特异性抗原(PSA)血清水平。结果:MSH2 (mutS homologue 2, MSH2)免疫表达与血清PSA水平、P53浓度呈显著正相关(p值0.001*)。MSH2免疫表达与肿瘤大小、淋巴结转移、远处转移及分级分型有显著相关性。而mutL同源物1 (MLH1)的免疫表达仅与人P53血清浓度显著相关(p值0.035*)。此外,MLH1免疫表达仅与淋巴结转移和肿瘤负荷相关,p值分别为0.033*和0.001*。结论:MMR蛋白丢失,尤其是MSH2,在前列腺癌的重要亚群中可见。有趣的是,它与血清PSA和p53水平显著升高有关。此外,它可能与肿瘤大、分级高、最终淋巴结和远处转移等不幸的预后特征有关。
{"title":"Assessment of mismatch repair proteins (MLH1 and MSH2) and p53 immunohistochemical expression in prostatic carcinoma: association with different clinicopathologic characteristics.","authors":"Hend S Abo Safia, Ahmed F Ghaith, Eman E Farghal, Basma S Amer","doi":"10.3332/ecancer.2025.1985","DOIUrl":"10.3332/ecancer.2025.1985","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is one of the most heritable human cancers and it is the second most frequent malignancy in men worldwide. It accounts for a significant morbidity and mortality throughout the world. PCa with mismatch repair (MMR) deficiency often has aggressive clinical and histological features, but its rarity prevents the analysis of the underlying biology. Therefore, in this study, we aimed to evaluate the immunohistochemical expression of MMR proteins and P53 in PCa.</p><p><strong>Materials and methods: </strong>Fifty cases of PCa were histologically examined. The MMR proteins and P53 immunoexpression were assessed. Also, P53 serum concentration levels using ELIZA was measured and pre-operative prostatic specific antigen (PSA) serum levels were obtained.</p><p><strong>Results: </strong>There was a significant positive relation between mutS homologue 2 (MSH2) immunoexpression and both PSA serum level and P53 serum concentration (<i>p</i> value 0.001*). Also, there was a significant relation between MSH2 immunoexpression and tumour size, nodal metastasis, distant metastasis and grade grouping. While mutL homologue 1 (MLH1) immunoexpression showed a significant relation with human P53 serum concentrations only (<i>p</i> value 0.035*). Moreover, MLH1 immunoexpression showed only significant relation with nodal metastasis and tumour burden, <i>p</i> value was 0.033* and 0.001*, respectively.</p><p><strong>Conclusion: </strong>MMR protein loss, especially MSH2, was seen in a significant subset of PCa. Interestingly, it was associated with significantly higher levels of serum PSA and p53. Moreover, it may be associated with unfortunate prognostic features as large tumour size, higher grade grouping and finally nodal and distant metastasis.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1985"},"PeriodicalIF":1.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An innovative model for integrated delivery of prevention, screening and palliative care services of cancers at health and wellness centres in Assam. 在阿萨姆邦的保健和保健中心综合提供癌症预防、筛查和姑息治疗服务的创新模式。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1983
Rewati Raman Rahul, Nandini Vallath, Kunal Oswal, Ravikant Singh, Kumar Gaurav, Paul Sebastian, Venkataramanan Ramachandran, Arnie Purushottham

There is a consensus on delivering prevention, early detection and palliative care services as effective cancer control strategies in primary healthcare settings; however, examples of practical application are few. The study describes the implementation of integrated delivery of preventive, early detection and palliative care needs assessment through the frontline healthcare workers at the Health and Wellness Centre. The study employed a master trainer team of dentist and nurses trained in prevention and needs assessment of palliative care services who would further provide the handhold training to the Community Health Officers (CHO), multi purpose workers and Accredited Social Health Activist for awareness, prevention and generalist palliative care needs assessment. 2106 households with 256 people were screened as a result, with an average of around 30 screenings a day. Screen positivity rates was found to be 3.1% for the oral cancer, for breast cancer it was 1.8% while for cervical cancer it was 3.4%. While 0.5% households were identified in need of palliative care, all screened positive cases were provided counselling for further diagnostics and care at the cancer centre in the district. The ambulance services of 102 available in the state were arranged for people willing to undergo the diagnostics. The evidence generated has the potential for practical application with further testing and strengthening in the field.

关于在初级卫生保健机构中提供预防、早期发现和姑息治疗服务作为有效的癌症控制战略,已达成共识;然而,实际应用的例子很少。该研究描述了通过卫生保健中心一线医护人员提供预防、早期检测和缓和医疗需求评估的综合服务的实施情况。该研究聘请了一个由接受过预防和姑息治疗服务需求评估培训的牙医和护士组成的主培训师团队,他们将进一步向社区卫生官员(CHO)、多用途工作人员和认可的社会卫生活动家提供关于认识、预防和全面姑息治疗需求评估的指导培训。结果,共有2106户家庭256人接受了检查,平均每天检查30次左右。口腔癌的筛查阳性率为3.1%,乳腺癌为1.8%而宫颈癌为3.4%。虽然确定了0.5%的家庭需要姑息治疗,但向所有筛查阳性病例提供了咨询,以便在该地区的癌症中心进一步诊断和治疗。该邦为愿意接受诊断的人安排了102辆救护车服务。所产生的证据有可能在实地进一步检验和加强后得到实际应用。
{"title":"An innovative model for integrated delivery of prevention, screening and palliative care services of cancers at health and wellness centres in Assam.","authors":"Rewati Raman Rahul, Nandini Vallath, Kunal Oswal, Ravikant Singh, Kumar Gaurav, Paul Sebastian, Venkataramanan Ramachandran, Arnie Purushottham","doi":"10.3332/ecancer.2025.1983","DOIUrl":"10.3332/ecancer.2025.1983","url":null,"abstract":"<p><p>There is a consensus on delivering prevention, early detection and palliative care services as effective cancer control strategies in primary healthcare settings; however, examples of practical application are few. The study describes the implementation of integrated delivery of preventive, early detection and palliative care needs assessment through the frontline healthcare workers at the Health and Wellness Centre. The study employed a master trainer team of dentist and nurses trained in prevention and needs assessment of palliative care services who would further provide the handhold training to the Community Health Officers (CHO), multi purpose workers and Accredited Social Health Activist for awareness, prevention and generalist palliative care needs assessment. 2106 households with 256 people were screened as a result, with an average of around 30 screenings a day. Screen positivity rates was found to be 3.1% for the oral cancer, for breast cancer it was 1.8% while for cervical cancer it was 3.4%. While 0.5% households were identified in need of palliative care, all screened positive cases were provided counselling for further diagnostics and care at the cancer centre in the district. The ambulance services of 102 available in the state were arranged for people willing to undergo the diagnostics. The evidence generated has the potential for practical application with further testing and strengthening in the field.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1983"},"PeriodicalIF":1.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An immune infiltration-based risk scoring system for prognostic stratification in colorectal adenocarcinoma. 基于免疫浸润的结直肠腺癌预后分层风险评分系统。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1982
Oluwafemi Ogundarea

Background: Colorectal adenocarcinoma (CRC) remains a leading cause of cancer-related mortality worldwide, with variable patient outcomes despite treatment advances. Traditional prognostic methods based on clinicopathological variables alone do not fully capture the biological complexity of the disease. This study aims to develop a risk scoring system based on genes associated with tumour-infiltrating immune cells (TIIC-associated genes) to improve prognostic assessment in CRC.

Methods: RNA-seq gene expression and clinicopathological data from The Cancer Genome Atlas Colorectal Adenocarcinoma (TCGA-CRC) database (647 tumour samples, 51 normal tissues) were analysed to identify differentially expressed TIIC-associated genes through comparison with the CIBERSORTx database. Univariate and multivariate Cox analyses were performed to screen for prognostic markers. A Gaussian mixture model was applied to cluster prognostic models and select the model with the most robust gene combination. The resulting risk scoring system was validated in an external cohort (GSE39582) and integrated with clinicopathological variables to develop a prognostic nomogram.

Results: From 128 TIIC-associated genes, an optimal prognostic model comprising CCL8 and Tyrosinase (TYR) was identified. The risk score was calculated as 0.152 × Exp(CCL8)-0.516 × Exp(TYR). Kaplan-Meier analysis confirmed significant survival differences between high-risk and low-risk groups in both TCGA-CRC and GSE39582 (p < 0.05). Time-dependent receiver operating characteristic analysis showed area under the curve (AUC) values ranging from 0.605 to 0.696 for 1-, 3- and 5-year survival in TCGA-CRC and GSE39582. Multivariate Cox analysis identified tumour (T stage), node (N stage) and risk score as independent prognostic factors.

Conclusion: Our risk scoring system based on CCL8 and TYR effectively stratifies CRC patients into distinct prognostic groups and could guide treatment decisions, particularly when integrated with TNM staging in a nomogram.

背景:结直肠腺癌(CRC)仍然是世界范围内癌症相关死亡的主要原因,尽管治疗进展,但患者预后不一。传统的基于临床病理变量的预后方法不能完全反映疾病的生物学复杂性。本研究旨在建立一种基于肿瘤浸润免疫细胞相关基因(tic -相关基因)的风险评分系统,以改善CRC的预后评估。方法:分析来自The Cancer Genome Atlas Colorectal Adenocarcinoma (TCGA-CRC)数据库(647例肿瘤样本,51例正常组织)的RNA-seq基因表达和临床病理数据,通过与CIBERSORTx数据库的比较,鉴定tiic相关基因的差异表达。进行单因素和多因素Cox分析以筛选预后标志物。采用高斯混合模型对预后模型进行聚类,选择基因组合鲁棒性最强的模型。由此产生的风险评分系统在外部队列(GSE39582)中得到验证,并与临床病理变量相结合,形成预后nomogram。结果:从128个tic相关基因中,确定了一个由CCL8和酪氨酸酶(TYR)组成的最佳预后模型。计算风险评分为0.152 × Exp(CCL8)-0.516 × Exp(TYR)。Kaplan-Meier分析证实,TCGA-CRC和GSE39582高危组与低危组的生存率均有显著差异(p < 0.05)。随时间变化的受试者工作特征分析显示,TCGA-CRC和GSE39582患者1、3和5年生存率的曲线下面积(AUC)值为0.605 ~ 0.696。多因素Cox分析发现肿瘤(T期)、淋巴结(N期)和危险评分是独立的预后因素。结论:我们基于CCL8和TYR的风险评分系统有效地将CRC患者划分为不同的预后组,并可以指导治疗决策,特别是在nomogram与TNM分期相结合时。
{"title":"An immune infiltration-based risk scoring system for prognostic stratification in colorectal adenocarcinoma.","authors":"Oluwafemi Ogundarea","doi":"10.3332/ecancer.2025.1982","DOIUrl":"10.3332/ecancer.2025.1982","url":null,"abstract":"<p><strong>Background: </strong>Colorectal adenocarcinoma (CRC) remains a leading cause of cancer-related mortality worldwide, with variable patient outcomes despite treatment advances. Traditional prognostic methods based on clinicopathological variables alone do not fully capture the biological complexity of the disease. This study aims to develop a risk scoring system based on genes associated with tumour-infiltrating immune cells (TIIC-associated genes) to improve prognostic assessment in CRC.</p><p><strong>Methods: </strong>RNA-seq gene expression and clinicopathological data from The Cancer Genome Atlas Colorectal Adenocarcinoma (TCGA-CRC) database (647 tumour samples, 51 normal tissues) were analysed to identify differentially expressed TIIC-associated genes through comparison with the CIBERSORTx database. Univariate and multivariate Cox analyses were performed to screen for prognostic markers. A Gaussian mixture model was applied to cluster prognostic models and select the model with the most robust gene combination. The resulting risk scoring system was validated in an external cohort (GSE39582) and integrated with clinicopathological variables to develop a prognostic nomogram.</p><p><strong>Results: </strong>From 128 TIIC-associated genes, an optimal prognostic model comprising CCL8 and Tyrosinase (TYR) was identified. The risk score was calculated as 0.152 × Exp(CCL8)-0.516 × Exp(TYR). Kaplan-Meier analysis confirmed significant survival differences between high-risk and low-risk groups in both TCGA-CRC and GSE39582 (<i>p</i> < 0.05). Time-dependent receiver operating characteristic analysis showed area under the curve (AUC) values ranging from 0.605 to 0.696 for 1-, 3- and 5-year survival in TCGA-CRC and GSE39582. Multivariate Cox analysis identified tumour (T stage), node (N stage) and risk score as independent prognostic factors.</p><p><strong>Conclusion: </strong>Our risk scoring system based on CCL8 and TYR effectively stratifies CRC patients into distinct prognostic groups and could guide treatment decisions, particularly when integrated with TNM staging in a nomogram.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1982"},"PeriodicalIF":1.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potentially avoidable emergency department visits among patients with advanced cancer. 晚期癌症患者可能避免的急诊就诊。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1984
Miguel Araujo-Meléndez, Mirza Jacqueline Alcalde-Castro, Andrea De-la-O-Murillo, Thierry Hernandez-Gilsoul, Enrique Soto-Perez-de-Celis, Roberto Gonzalez-Salazar, Yanin Chavarri-Guerra

Background: Potentially avoidable emergency department (ED) visits are considered an indicator of the quality of cancer care.

Objective: To investigate the causes of ED visits of patients with advanced cancer.

Methods: We included in this analysis the visits to the ED of patients with advanced cancer in a tertiary cancer center in Mexico City, registered the reasons for their visit, and classified them as potentially avoidable or not by three independent observers.

Results: Seventy-seven patients were included, and 69% had at least one visit to the ED. Fifty-seven percent of visits were classified as potentially avoidable. The most common causes of visiting the ED were: pain, gastrointestinal disorders and ascites. Patients with gastrointestinal and genitourinary tumours had a higher frequency of unavoidable ED visits compared to patients with other tumours (43.3% versus 20.7%, p 0.03).

Conclusion: A significant proportion of patients with advanced cancer visit the ED and many of these visits were classified as potentially avoidable based on expert judgment and adapted criteria. These findings highlight the need for further research and context-specific strategies, such as care and early palliative integration, to safely reduce unnecessary ED use and enhance quality of life in low- and middle-income settings.

背景:潜在可避免的急诊科(ED)访问被认为是癌症护理质量的一个指标。目的:探讨晚期癌症患者急诊科就诊的原因。方法:我们将墨西哥城某三级癌症中心晚期癌症患者到急诊科就诊的情况纳入分析,记录其就诊原因,并由三名独立观察员将其分类为可避免或不可避免。结果:77名患者被纳入研究,69%的患者至少去了一次急诊科。57%的患者被归类为可能可以避免的。到急诊科就诊的最常见原因是:疼痛、胃肠道紊乱和腹水。与其他肿瘤患者相比,胃肠道和泌尿生殖系统肿瘤患者不可避免的ED就诊频率更高(43.3%比20.7%,p 0.03)。结论:根据专家判断和适应标准,有相当比例的晚期癌症患者就诊于急诊科,其中许多就诊被归类为可能可以避免的。这些发现强调需要进一步研究和具体情况的策略,例如护理和早期姑息治疗整合,以安全地减少不必要的ED使用并提高低收入和中等收入环境中的生活质量。
{"title":"Potentially avoidable emergency department visits among patients with advanced cancer.","authors":"Miguel Araujo-Meléndez, Mirza Jacqueline Alcalde-Castro, Andrea De-la-O-Murillo, Thierry Hernandez-Gilsoul, Enrique Soto-Perez-de-Celis, Roberto Gonzalez-Salazar, Yanin Chavarri-Guerra","doi":"10.3332/ecancer.2025.1984","DOIUrl":"10.3332/ecancer.2025.1984","url":null,"abstract":"<p><strong>Background: </strong>Potentially avoidable emergency department (ED) visits are considered an indicator of the quality of cancer care.</p><p><strong>Objective: </strong>To investigate the causes of ED visits of patients with advanced cancer.</p><p><strong>Methods: </strong>We included in this analysis the visits to the ED of patients with advanced cancer in a tertiary cancer center in Mexico City, registered the reasons for their visit, and classified them as potentially avoidable or not by three independent observers.</p><p><strong>Results: </strong>Seventy-seven patients were included, and 69% had at least one visit to the ED. Fifty-seven percent of visits were classified as potentially avoidable. The most common causes of visiting the ED were: pain, gastrointestinal disorders and ascites. Patients with gastrointestinal and genitourinary tumours had a higher frequency of unavoidable ED visits compared to patients with other tumours (43.3% versus 20.7%, <i>p</i> 0.03).</p><p><strong>Conclusion: </strong>A significant proportion of patients with advanced cancer visit the ED and many of these visits were classified as potentially avoidable based on expert judgment and adapted criteria. These findings highlight the need for further research and context-specific strategies, such as care and early palliative integration, to safely reduce unnecessary ED use and enhance quality of life in low- and middle-income settings.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1984"},"PeriodicalIF":1.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging gaps in breast cancer care: a Breast Cancer Care Quality Index to improve outcomes worldwide. 弥合乳腺癌护理的差距:乳腺癌护理质量指数改善世界范围内的结果。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-09-01 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1981
Eduardo Cazap, Benjamin O Anderson, Giuseppe Curigliano, Sandeep Sehdev, Fatima Cardoso, Ana Rita Gonzalez, Emad Shash, Cheng-Har Yip, André Mattar, Yanin Chavarri-Guerra, Miriam Mutebi, Yongmei Yin, João Victor Rocha, Ilaria Lucibello, Namita Srivastava

Background: Breast cancer (BC) care faces challenges in early detection, timely diagnosis and comprehensive management. Disparities persist, with underserved populations facing the greatest barriers. Addressing these requires policies that support consistent, evidence-based practices and enhance healthcare capacity and technology advancements. This document presents the development of the Breast Cancer Care Quality Index (BCCQI), supported by evidence to promote equitable care and improve BC outcomes globally, and discusses its adoption as a strategic tool within National Cancer Control Plans.

Methods: A two-part methodology identified challenges in BC care and defined dimensions, targets and indicators for the BCCQI, aligned with the World Health Organization Global Breast Cancer Initiative. A literature review and analysis of existing United Nations (UN) frameworks informed the initial structure of the index, which was later refined through expert feedback from a multidisciplinary panel representing diverse backgrounds and geographies.

Findings: The BCCQI is organised into four dimensions, comprising 10 targets and 23 indicators to guide the development of country-specific roadmaps. It should promote progress across key domains: health equity, patient centricity, universal access, care quality and treatment effectiveness. The Index is conceived as a dynamic tool, continuously refined through real-world application and emerging evidence.

Interpretation: Despite the previous initiatives, progress has been slow, likely due to practical details and country-specific guidance remaining limited due to scarce real-world evidence. Promoting national ownership and empowering action aligned with local challenges and opportunities, a flexible, strategic framework may help address these gaps.

背景:乳腺癌的早期发现、及时诊断和综合管理面临着诸多挑战。差距依然存在,服务不足的人群面临最大的障碍。解决这些问题需要政策支持一致的、基于证据的实践,并增强医疗保健能力和技术进步。本文介绍了乳腺癌护理质量指数(BCCQI)的发展,以证据支持促进公平护理和改善全球乳腺癌结果,并讨论了将其作为国家癌症控制计划中的战略工具。方法:根据世界卫生组织全球乳腺癌倡议,采用两部分方法确定了乳腺癌护理面临的挑战,并确定了BCCQI的维度、目标和指标。对现有联合国框架的文献审查和分析为该指数的初步结构提供了依据,随后通过代表不同背景和地域的多学科小组的专家反馈对该指数进行了完善。结果:BCCQI分为四个维度,包括10个目标和23个指标,以指导具体国家路线图的制定。它应促进在卫生公平、以患者为中心、普遍可及、护理质量和治疗效果等关键领域取得进展。该指数被认为是一个动态工具,通过现实世界的应用和新出现的证据不断完善。解释:尽管之前采取了一些举措,但进展缓慢,可能是由于缺乏实际证据,实际细节和针对具体国家的指导仍然有限。一个灵活的战略框架可以促进国家自主,并根据当地的挑战和机遇赋予行动权力,从而有助于解决这些差距。
{"title":"Bridging gaps in breast cancer care: a Breast Cancer Care Quality Index to improve outcomes worldwide.","authors":"Eduardo Cazap, Benjamin O Anderson, Giuseppe Curigliano, Sandeep Sehdev, Fatima Cardoso, Ana Rita Gonzalez, Emad Shash, Cheng-Har Yip, André Mattar, Yanin Chavarri-Guerra, Miriam Mutebi, Yongmei Yin, João Victor Rocha, Ilaria Lucibello, Namita Srivastava","doi":"10.3332/ecancer.2025.1981","DOIUrl":"10.3332/ecancer.2025.1981","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) care faces challenges in early detection, timely diagnosis and comprehensive management. Disparities persist, with underserved populations facing the greatest barriers. Addressing these requires policies that support consistent, evidence-based practices and enhance healthcare capacity and technology advancements. This document presents the development of the Breast Cancer Care Quality Index (BCCQI), supported by evidence to promote equitable care and improve BC outcomes globally, and discusses its adoption as a strategic tool within National Cancer Control Plans.</p><p><strong>Methods: </strong>A two-part methodology identified challenges in BC care and defined dimensions, targets and indicators for the BCCQI, aligned with the World Health Organization Global Breast Cancer Initiative. A literature review and analysis of existing United Nations (UN) frameworks informed the initial structure of the index, which was later refined through expert feedback from a multidisciplinary panel representing diverse backgrounds and geographies.</p><p><strong>Findings: </strong>The BCCQI is organised into four dimensions, comprising 10 targets and 23 indicators to guide the development of country-specific roadmaps. It should promote progress across key domains: health equity, patient centricity, universal access, care quality and treatment effectiveness. The Index is conceived as a dynamic tool, continuously refined through real-world application and emerging evidence.</p><p><strong>Interpretation: </strong>Despite the previous initiatives, progress has been slow, likely due to practical details and country-specific guidance remaining limited due to scarce real-world evidence. Promoting national ownership and empowering action aligned with local challenges and opportunities, a flexible, strategic framework may help address these gaps.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1981"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and treatment profile with five-year survival analysis of colorectal cancer from Himalayan state of India. 印度喜马拉雅邦结直肠癌的临床和治疗概况及5年生存分析。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-08-29 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1979
Kaushal Singh Rathore, U K Chandel, Niharika Singh

Background: The incidence of colorectal cancer has been increasing worldwide. Middle- and low-income countries are also experiencing surge. This is due to a rapidly growing population.

Methods: All patients diagnosed and presenting to Indira Gandhi Medical College, Shimla, the sole tertiary cancer care centre in Himachal Pradesh, India, during the study period from January 2017 to December 2018, were included in the study and were followed till 60 months. Data were collected on clinical characteristics, pathology, treatment received and survival outcomes, specifically overall survival (OS) and disease-free survival (DFS). A Kaplan-Meier survival curve was constructed and multiple regression analysis was conducted to identify factors influencing survival, with a significance level set at p < 0.05.

Results: A total of 165 patients participated in the study, with a predominance of male subjects, a median age of 60 years and 34% of participants being under 50 years of age. The most prevalent symptoms were anorexia and weight loss, affecting 97% of the cohort, with the rectum identified as the most common site of involvement in 42% of cases. Histopathological analysis revealed signet ring-type morphology in 15% of the cases. The majority of patients presented with advanced stages, specifically stage 3 (36%) and stage 4 (32%). A multimodal treatment strategy was employed, involving collaboration among radiation oncologists, surgeons and medical oncologists. After a follow-up period of 60 months, 22 patients were lost to follow-up and only 23 patients remained alive. Multiple regression analysis indicated that only the stage of the disease significantly influenced overall survival (OS) and DFS.

Conclusion: Limited health awareness, coupled with the challenging topography of the region, has led to a significant number of defaulters. This, in conjunction with the advanced stage of the disease and inadequate access to healthcare, has contributed to suboptimal OS and DFS rates. Further epidemiological investigations, including genetic analyses, are necessary to better characterise the presentation of this disease.

背景:结直肠癌的发病率在世界范围内呈上升趋势。中低收入国家也在经历增长。这是由于人口的迅速增长。方法:在2017年1月至2018年12月的研究期间,所有在印度喜马偕尔邦唯一的三级癌症护理中心西姆拉英迪拉甘地医学院诊断并就诊的患者都被纳入研究,随访至60个月。收集临床特征、病理、接受治疗和生存结果的数据,特别是总生存期(OS)和无病生存期(DFS)。构建Kaplan-Meier生存曲线,进行多元回归分析,确定影响生存的因素,显著性水平设为p < 0.05。结果:共165例患者参与研究,以男性受试者为主,中位年龄60岁,年龄在50岁以下的患者占34%。最常见的症状是厌食和体重减轻,影响了97%的队列,其中直肠被确定为最常见的受累部位,占42%。组织病理学分析显示印戒型形态在15%的病例。大多数患者表现为晚期,特别是3期(36%)和4期(32%)。采用了多模式治疗策略,包括放射肿瘤学家、外科医生和内科肿瘤学家之间的合作。经过60个月的随访,22例患者失访,仅23例患者存活。多元回归分析表明,只有疾病分期对总生存期(OS)和DFS有显著影响。结论:卫生意识有限,再加上该地区地形复杂,导致了大量的违约者。这一点,再加上疾病的晚期阶段和获得保健服务的机会不足,导致总生存时间和死亡时间低于理想水平。需要进一步的流行病学调查,包括遗传分析,以更好地描述这种疾病的表现。
{"title":"Clinical and treatment profile with five-year survival analysis of colorectal cancer from Himalayan state of India.","authors":"Kaushal Singh Rathore, U K Chandel, Niharika Singh","doi":"10.3332/ecancer.2025.1979","DOIUrl":"10.3332/ecancer.2025.1979","url":null,"abstract":"<p><strong>Background: </strong>The incidence of colorectal cancer has been increasing worldwide. Middle- and low-income countries are also experiencing surge. This is due to a rapidly growing population.</p><p><strong>Methods: </strong>All patients diagnosed and presenting to Indira Gandhi Medical College, Shimla, the sole tertiary cancer care centre in Himachal Pradesh, India, during the study period from January 2017 to December 2018, were included in the study and were followed till 60 months. Data were collected on clinical characteristics, pathology, treatment received and survival outcomes, specifically overall survival (OS) and disease-free survival (DFS). A Kaplan-Meier survival curve was constructed and multiple regression analysis was conducted to identify factors influencing survival, with a significance level set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>A total of 165 patients participated in the study, with a predominance of male subjects, a median age of 60 years and 34% of participants being under 50 years of age. The most prevalent symptoms were anorexia and weight loss, affecting 97% of the cohort, with the rectum identified as the most common site of involvement in 42% of cases. Histopathological analysis revealed signet ring-type morphology in 15% of the cases. The majority of patients presented with advanced stages, specifically stage 3 (36%) and stage 4 (32%). A multimodal treatment strategy was employed, involving collaboration among radiation oncologists, surgeons and medical oncologists. After a follow-up period of 60 months, 22 patients were lost to follow-up and only 23 patients remained alive. Multiple regression analysis indicated that only the stage of the disease significantly influenced overall survival (OS) and DFS.</p><p><strong>Conclusion: </strong>Limited health awareness, coupled with the challenging topography of the region, has led to a significant number of defaulters. This, in conjunction with the advanced stage of the disease and inadequate access to healthcare, has contributed to suboptimal OS and DFS rates. Further epidemiological investigations, including genetic analyses, are necessary to better characterise the presentation of this disease.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1979"},"PeriodicalIF":1.3,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to screening of breast and cervical cancer among women in remote villages of Karnataka: an analysis using the Health Belief Model. 卡纳塔克邦偏远村庄妇女乳腺癌和宫颈癌筛查的障碍:使用健康信念模型的分析。
IF 1.3 Q4 ONCOLOGY Pub Date : 2025-08-29 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1980
Mayank Chhabra, Somika Meet, Gandhar Tendulkar, Kunal Oswal, Milan Toraskar, Sai Murali, Bharat Kumar Sarvepalli, Sripriya Rao, Ramachandran Venkataramanan, Yogesh Jain

Background: Cancer remains a significant public health challenge, being the second leading cause of death in urban areas and the fourth in rural regions of India. The estimated 1.15 million new cancer cases in 2018 are projected to double by 2040. Despite the critical importance of early detection, cancer screening rates in rural India remain alarmingly low. This study investigates barriers to breast and cervical screening among women in remote villages of Karnataka using the Health Belief Model (HBM) as a theoretical framework.

Methods: A community-based screening program for oral, breast and cervical cancer, was implemented in three taluks of Chikkaballapur district, Karnataka, from September to November 2021. Quantitative data from 4,974 screened women were complemented by qualitative interviews with 292 women who did not consent to screening, particularly for breast and cervical cancer. Interviews were guided by HBM constructs perceived susceptibility, severity, barriers, benefits, cues to action and self-efficacy and analysed thematically.

Results: Out of the 4,974 women who participated in screening clinics, less than 10% consented to clinical breast examination and none to cervical screening. Major barriers to screening included socio-cultural factors (stigma, lack of awareness, peer pressure), economic constraints (work priorities and financial insecurity), psychological barriers (fear of outcomes and lack of healthcare trust) and physical challenges (accessibility and seasonal constraints). Fear of treatment outcomes and financial implications were prominent psychological deterrents. Mitigation strategies were noted to address these barriers, including awareness campaigns, flexible camp timings and local stakeholder engagement.

Conclusion: Addressing barriers to cervical and breast cancer screening requires a holistic, community-centred approach informed by theoretical models like HBM. Sustainable interventions must prioritise awareness, accessibility and affordability to bridge critical healthcare gaps and reduce the burden of cancer in rural India.

背景:癌症仍然是一项重大的公共卫生挑战,是印度城市地区第二大死因,农村地区第四大死因。2018年估计有115万例新发癌症病例,预计到2040年将翻一番。尽管早期发现至关重要,但印度农村地区的癌症筛查率仍然低得惊人。本研究使用健康信念模型(HBM)作为理论框架,调查了卡纳塔克邦偏远村庄妇女进行乳房和子宫颈筛查的障碍。方法:2021年9月至11月,在卡纳塔克邦奇卡巴拉普尔县的三个县实施了一项以社区为基础的口腔、乳腺癌和宫颈癌筛查项目。对4,974名接受筛查的妇女的定量数据进行了补充,并对292名不同意接受筛查的妇女进行了定性访谈,特别是对乳腺癌和宫颈癌的筛查。访谈以认知易感性、严重性、障碍、益处、行动线索和自我效能等HBM构念为指导,并进行主题分析。结果:在参加筛查诊所的4,974名妇女中,只有不到10%的人同意进行临床乳房检查,没有人同意进行子宫颈筛查。筛查的主要障碍包括社会文化因素(耻辱、缺乏意识、同侪压力)、经济限制(工作重点和财务不安全)、心理障碍(对结果的恐惧和缺乏医疗保健信任)和身体挑战(可及性和季节性限制)。对治疗结果的恐惧和经济影响是主要的心理障碍。与会者指出了解决这些障碍的缓解战略,包括提高认识运动、灵活的营地时间安排和当地利益攸关方的参与。结论:解决宫颈癌和乳腺癌筛查的障碍需要一种全面的、以社区为中心的方法,这种方法由HBM等理论模型提供信息。可持续的干预措施必须优先考虑认识、可及性和可负担性,以弥合关键的医疗保健差距并减轻印度农村的癌症负担。
{"title":"Barriers to screening of breast and cervical cancer among women in remote villages of Karnataka: an analysis using the Health Belief Model.","authors":"Mayank Chhabra, Somika Meet, Gandhar Tendulkar, Kunal Oswal, Milan Toraskar, Sai Murali, Bharat Kumar Sarvepalli, Sripriya Rao, Ramachandran Venkataramanan, Yogesh Jain","doi":"10.3332/ecancer.2025.1980","DOIUrl":"10.3332/ecancer.2025.1980","url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a significant public health challenge, being the second leading cause of death in urban areas and the fourth in rural regions of India. The estimated 1.15 million new cancer cases in 2018 are projected to double by 2040. Despite the critical importance of early detection, cancer screening rates in rural India remain alarmingly low. This study investigates barriers to breast and cervical screening among women in remote villages of Karnataka using the Health Belief Model (HBM) as a theoretical framework.</p><p><strong>Methods: </strong>A community-based screening program for oral, breast and cervical cancer, was implemented in three taluks of Chikkaballapur district, Karnataka, from September to November 2021. Quantitative data from 4,974 screened women were complemented by qualitative interviews with 292 women who did not consent to screening, particularly for breast and cervical cancer. Interviews were guided by HBM constructs perceived susceptibility, severity, barriers, benefits, cues to action and self-efficacy and analysed thematically.</p><p><strong>Results: </strong>Out of the 4,974 women who participated in screening clinics, less than 10% consented to clinical breast examination and none to cervical screening. Major barriers to screening included socio-cultural factors (stigma, lack of awareness, peer pressure), economic constraints (work priorities and financial insecurity), psychological barriers (fear of outcomes and lack of healthcare trust) and physical challenges (accessibility and seasonal constraints). Fear of treatment outcomes and financial implications were prominent psychological deterrents. Mitigation strategies were noted to address these barriers, including awareness campaigns, flexible camp timings and local stakeholder engagement.</p><p><strong>Conclusion: </strong>Addressing barriers to cervical and breast cancer screening requires a holistic, community-centred approach informed by theoretical models like HBM. Sustainable interventions must prioritise awareness, accessibility and affordability to bridge critical healthcare gaps and reduce the burden of cancer in rural India.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1980"},"PeriodicalIF":1.3,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ecancermedicalscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1